Ulf Wiinberg, the former chief executive of H. Lundbeck A/S, has joined the board of Agenus Inc as an independent director. Agenus is developing checkpoint inhibitor and modulator antibodies for cancer. Mr Wiinberg previously held senior positions at Wyeth which is now part of Pfizer Inc. He currently serves on the boards of UCB SA of Belgium, Avillion LLP of the UK and Nestle Health Science SA of Switzerland.
Agenus announced the appointment on 19 May 2016.
Copyright 2016 Evernow Publishing Ltd